✦ LIBER ✦

Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study

✍ Scribed by Heigener, David F.; Wu, Yi-Long; van Zandwijk, Nico; Mali, Pekka; Horwood, Keith; Reck, Martin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival outcomes in patients with advan

✍ Van Meerbeeck, J.; Galdermans, D.; Bustin, F.; De Vos, L.; Lechat, I.; Abraham, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Second-line chemotherapy with weekly pac

✍ Luis Ángel León Mateos; Juan Fernando Cueva Bañuelos; María Teresa Curiel García 📂 Article 📅 2002 🏛 Springer Milan 🌐 Spanish ⚖ 49 KB

Efficacy of erlotinib in patients with a

✍ Michael BOYER; Keith HORWOOD; Nick PAVLAKIS; Paul DE SOUZA; Michael MILLWARD; Br 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

6510 ORAL Erlotinib in patients with adv

✍ Smit, E.; Reck, M.; Krzakowski, M.; Gridelli, C.; Curescu, S.; Berzinec, P.; Bar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Advances in the treatment of second-line

✍ Hanna, N. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 179 KB